About CytoPherx
CytoPherx is a company based in Ann Arbor (United States) founded in 1994. CytoPherx has raised $47.69 million across 3 funding rounds from investors including Early Stage Partners, ONSET Ventures and Capital Midwest Fund. CytoPherx has completed 1 acquisition, including Immunocept Medical Products. CytoPherx operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others.
- Headquarter Ann Arbor, United States
- SectorsHealthcare
- Website cytopherx.com
- Total Equity Funding$47.69M (USD)
in 3 rounds
- Latest Funding Round$34M (USD), Series B
Jan 2012
- InvestorsEarly Stage Partners
& 5 more
- Investments & Acquisitions
Funding Insights of CytoPherx
CytoPherx has successfully raised a total of $47.69M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $47.69M
- Total Rounds 3
- Last Round Series B — $34M
- First Round $2M
(Nov 2009)
- Investors Count 6
All 3 funding rounds of CytoPherx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $34M | Series B | – | Early Stage Partners, ONSET Ventures | – |
| Jun 2010 | $11.69M | Series A | – | – | – |
| Nov 2009 | $2M | Unspecified | – | – | – |
6 investors in total: 6 institutional.
Investors in CytoPherx
CytoPherx has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Early Stage Partners, ONSET Ventures and Capital Midwest Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US tech companies are made. | 2001 | esplp.com | Cleveland, United States | |
Early stage VC firm investing in the US | – | onset.com | Menlo Park, United States | |
- | – | capitalmidwest.com | - | |
Tech and Life Sciences focused corporate VC firm investing in the US | – | kpventures.com | Oakland, United States | |
Funding and expertise are provided for medical device development. | 2017 | emvllp.com | San Jose, United States | |
Tech and life sciences focused VC firm investing in geographies such as the US | – | aphelioncapital.net | Mill Valley, United States |
Investor details for CytoPherx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CytoPherx
1 people are tracked at CytoPherx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Charles Fisher | CEO | Leadership |
Complete people profiles for CytoPherx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytoPherx
CytoPherx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immunocept Medical Products.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Blood filtration therapy for severe sepsis is developed. | immunocept.com | Denver, United States | 1999 | Jun 2018 | •••• |
Complete acquisition details for CytoPherx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CytoPherx
4 dated milestones of CytoPherx across 24 years, from founding to its latest funding, stage changes and deals.
- Founded CytoPherx is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $34.0M.
- Acquisition Acquires Immunocept Medical Products.
Competitors of CytoPherx
CytoPherx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hemotune.ch | 2017 | Zurich, Switzerland | $28.86M | – | Developer of a device for blood purification | |
| medcurainc.com | 2019 | United States | $87.35M | – | Developer of the device for controlling bleeding | |
| extheramedical.com | 2007 | Berkeley, United States | $54.59M | 23 | Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | |
| lindis-bloodcare.com | 2006 | Hennigsdorf, Germany | $1.89M | – | Innovative solutions for safer blood transfusions are developed. | |
| arteriocyte.com | 2007 | Hopkinton, United States | $15.11M | 7 | Devices to facilitate blood component and bone marrow transplant | |
| artblood.kr | 2022 | Seoul, South Korea | $4.8M | – | Developer of a cell-based extracorporeal blood production system | |
| antrad.se | 2008 | Stockholm, Sweden | $3.5M | – | Thawed, ready to use blood plasma | |
| syngeninc.com | 2009 | Sacramento, United States | $16.81M | – | Develops cell separation tools and accessories | |
| veli.co | 1992 | Beverly, United States | – | 33 | Developer of blood and plasma products for transfusion |
Detailed competitors of CytoPherx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to CytoPherx
10 companies that operate in the same segment as CytoPherx (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CytoPherx
CytoPherx was founded in 1994 and raised its 1st funding round 15 years after it was founded.
CytoPherx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Charles Fisher is the current CEO of CytoPherx.
CytoPherx is a funded company, having raised a total of $47.69M across 3 funding rounds to date. The company's 1st funding round was a Unspecified of $2M, raised on Nov 2009.
Founded in 1994 as Nephrion and renamed CytoPherx in 2009, the company operates in the medical device sector from Ann Arbor, United States. Systems are designed to sequester and deactivate leucocytes in the circulatory system, utilizing hollow fiber dialysis filters. Targets include acute renal failure, end-stage renal disease, and inflammation from cardiopulmonary bypass surgery. Leadership is provided by CEO Charles Fisher.
CytoPherx's top competitors include Medcura, ExThera Medical and Lindis Blood Care.
CytoPherx has made 1 acquisition, including Immunocept Medical Products.
CytoPherx has 6 investors. Key investors include Early Stage Partners, ONSET Ventures, Capital Midwest Fund, Kaiser Permanente Ventures, and Emergent Medical Partners.